Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms

International Journal of Psychiatry in Clinical Practice

Volumn 13, Issue 4, 2009, Pages 345-348

  Van Nieuwerburgh, Filip C W ^a   Denys, Damiaan A J P ^b   Westenberg, Herman G M ^c   Deforce, Dieter L D ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Blood levels; CYP2D6; Obsessive compulsive disorder; OCD; Paroxetine; Plasma levels; Polymorphisms; Response; Venlafaxine

Indexed keywords

CYTOCHROME P450 2D6; DESVENLAFAXINE; DNA; PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 70350771152     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651500902903016     Document Type: Article

References (14)

1. Goodman WK,Ward HE, Murphy TK. Biologic approaches to treatment-refractory obsessive-compulsive disorder. Psychiatr Ann 1998;/28(11):/641-9.
2. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 2007;/ 68(5):/747-53.
3. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. Cyp2d6 and cyp2c19 genotype-based dose recommendations for antidepressants: A first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;/ 104(3):/173-92.
4. Denys D, van Megen HJGM, van der Wee N, Westenberg HGM. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;/65(1):/37-43.
5. Tournel G, Houdret N, Hedouin V, Deveaux M, Gosset D, Lhermitte M. High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. J Chromatogr B Anal Technol Biomed Life Sci 2001;/761(2):/147-58.
6. Marez D, Legrand M, Sabbagh N, LoGuidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome p450 cyp2d6 gene in a european population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;/7(3):/193-202.
7. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelmansundberg M. Genetic-analysis of the chinese cytochrome p4502d locus- characterization of variant cyp2d6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;/46(3):/ 452-9.
8. Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, et al. A novel intronic mutation, 2988g-a, with high predictivity for impaired function of cytochrome p450 2d6 in white subjects. Clin Pharmacol Ther 2004;/ 76(2):/128-38.
9. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, et al. Genetic variation in eleven phase i drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004;/5(7):/895-931.
10. Bradford LD. Cyp2d6 allele frequency in european caucasians, asians, africans and their descendants. Pharmacogenomics 2002;/3(2):/229-43.
11. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007;/ 164(Suppl 7):/5-53.
12. Denys D, van der Wee N, van Megen HJGM, Westenberg HGM. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;/23(6):/568-75.
13. Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003;/64(9):/1113-21. (Pubitemid 37158259)
14. YaryuraTobias JA, Neziroglu FA. Venlafaxine in obsessivecompulsive disorder. Arch Gen Psychiatry 1996;/53(7):/ 653-4.